Your session is about to expire
← Back to Search
Interleukin-1 (IL-1) Antagonist
Anakinra 100Mg/0.67Ml Inj Syringe for Endometriosis
Phase < 1
Waitlist Available
Led By Sanjay K Agarwal, MD
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up subjects will complete the baseline questionnaire at visit 1. subjects will fill out monthly questionnaires after the administration of either anakinra or placebo during 6 menstrual periods.
Awards & highlights
Study Summary
This study is evaluating whether a medication which is used to treat rheumatoid arthritis may help reduce pain for women with endometriosis.
Eligible Conditions
- Endometriosis
- Anakinra
- Markers of Inflammation
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ subjects will complete the baseline questionnaire at visit 1. subjects will fill out monthly questionnaires after the administration of either anakinra or placebo during 6 menstrual periods.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~subjects will complete the baseline questionnaire at visit 1. subjects will fill out monthly questionnaires after the administration of either anakinra or placebo during 6 menstrual periods.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Comparison of the impact of anakinra versus placebo on menstrual pain (dysmenorrhea) using the modified Biberoglu and Behrman scale.
Secondary outcome measures
Comparison of serum inflammatory markers before and after anakinra administration.
Comparison of the impact of anakinra versus placebo on dyspareunia and non menstrual pelvic pain using the modified Biberoglu and Behrman scale.
Comparison of the impact of anakinra versus placebo on the quality of life using the Endometriosis Health Profile 30 questionnaire (EHP-30), conducted after each course of study medication administration.
Side effects data
From 2018 Phase 2 & 3 trial • 104 Patients • NCT0180913219%
Acute Kidney Injury
11%
Ascites
9%
Nausea
9%
Urinary tract infection
8%
Hematemesis
8%
Upper GI hemorrhage
8%
Clostridium difficile infection
6%
Hepatic failure
6%
Encephalopathy
6%
C. difficile infection
4%
Respiratory Failure
4%
Peritonitis
4%
Esophageal varices hemorrhage
4%
Tachycardia
4%
Multiple Organ Dysfunction Syndrome (MODS)
2%
Viremia
2%
Baceteremia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Anakinra & Pentoxifylline & Zinc Sulfate
Methylprednisolone
Observational
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active Treatment with AnakinraExperimental Treatment1 Intervention
10 subjects will be enrolled in this group. Initial treatment will consist of 100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection from within 24 hours of the onset of menses until within 24 hours of last menstrual day.
Group II: Standard ComparisonPlacebo Group1 Intervention
10 subjects will be enrolled in this group. This group will be given placebo injections as their initial treatment. The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection. These individuals will self-administer the placebo each evening by subcutaneous injection from within 24 hours of the onset of menses until within 24 hours of last menstrual day.
Find a Location
Who is running the clinical trial?
University of California, San DiegoLead Sponsor
1,123 Previous Clinical Trials
1,552,819 Total Patients Enrolled
Sanjay K Agarwal, MDPrincipal InvestigatorUC San Diego
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger